Menu Search

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)632.58
  • Today's Change0.584 / 0.09%
  • Shares traded15.15k
  • 1 Year change-3.86%
  • Beta0.1752
Data delayed at least 20 minutes, as of May 03 2024 12:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in GBPView more

Cash flow information is not available for International Biotechnology Trust.
Cash flow per share--
Price/Cash flow per share--
Book value per share6.88
Tangible book value per share6.88
More ▼

Balance sheet in GBPView more

International Biotechnology Trust has a Debt to Total Capital ratio of 10.73%.
Current ratio0.0859
Quick ratio--
Total debt/total equity0.1201
Total debt/total capital0.1073
More ▼

Growth rates in GBP

Year on year, growth in dividends per share fell -5.39% while earnings per share excluding extraordinary items rose 130.68%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)3.43%
Div growth rate (5 year)0.43%
Payout ratio (TTM)167.43%
EPS growth(5 years)-20.59
EPS (TTM) vs
TTM 1 year ago		130.44
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.